Intervention: Ledipasvir and sofosbuvir
Trial phase: Phase 4
ATC code: J05AP51
SMILES: CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1.COC(=O)NC(C(=O)N1CC2(CC2)CC1c1ncc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5nc(C6C7CCC(C7)N6C(=O)C(NC(=O)OC)C(C)C)[nH]c5c4)ccc2-3)[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.

sofosbuvir/ledipasvir: sofosbuvir ledipasvir fixed dose combination given once a day by mouth
Eligibility criteria:
Inclusion Criteria:

Willing and able to provide written informed consent.
Male or female >18 years of age
Serum HCV RNA levels of >1,000 IU per milliliter or higher

HCV treatment experienced or naïve.

HCV treatment naïve: No prior exposure to any Interferon, ribavirin, or other approved or experimental HCV-specific directly acting antivirals
HCV Treatment-Experienced: Virologic failure after treatment with Pegylated interferon + ribavirin, Non-structural 3/4a (NS3/4A) protease inhibitor plus pegylated interferon + ribavirin, or regimen of sofosbuvir±ribavirin± pegylated interferon regimen.
Chronic Hepatitis C based on the judgment of the investigator
HCV genotype 1, 2, 3, 4
If the patient is determined to be cirrhotic (based on criteria outlined earlier), the patient must have an ultrasound done within 6 months prior to enrollment with no evidence of hepatocellular carcinoma.

Indolent Non-Hodgkin's lymphoma , which may include the following :

Nodal Marginal zone lymphoma
Extranodal marginal zone lymphoma (MALT)
Splenic marginal zone lymphoma

Follicular lymphoma Grade 1-3a with low tumor burden*, FLIPI 2 risk category of either low (i.e. no risk factors) or intermediate (1-2 risk factors), and with no B symptoms. B symptoms are defined as:

Fever (i.e., temperature >38°C [>100.4°F]) for 3 consecutive days
Weight loss exceeding 10% of body weight in 6 months
Drenching night sweats
Lymphoplasmacytic lymphoma

No prior chemotherapy

Low tumor burden is defined as normal lactate dehydrogenase, largest nodal or extranodal mass less than 7 cm, up to three nodal sites containing nodes with a diameter greater than 3 cm, no clinically significant serous effusions detectable by physical examination or positron emission tomography (PET)/CT scan, and spleen enlargement up to 16 cm by CT without any evidence of portal hypertension.
Karnofsky performance status > 70%
Creatinine clearance ≥60 mL/min, as calculated by Cockcroft-Gault equation

If patient will need ribavirin in their regimen then the following inclusion:

Hg >12 g/dL for male
Hg >11 g/dL for female
All women of child-bearing potential who take ribavirin will need to have a negative urine pregnancy test.

Exclusion Criteria:

Life expectancy < 6 months
Any HCV treatment which uses pegylated interferon
HCV genotype 3 Treatment experienced with cirrhosis
Co-infection with hepatitis B
Prior chemotherapy for lymphoma
Lymphomas of other histologies other than the ones listed in section 3.3 above
Follicular lymphoma with large cell transformation
Decompensated liver disease in which pegylated interferon is contraindicated.
Female who is pregnant or breast feeding and HCV treatment requires use of ribavirin.
Solid organ transplant
Any interferon- containing agent within 8 weeks prior to screening or any prior exposure to HCV-specific antivirals agent(s), other than NS3/ 4A protease inhibitor and sofosbuvir
Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients.
On a prohibited medication which cannot be stopped during the duration of HCV treatment.
Female subject who is pregnant or breastfeeding
HIV-infection